New York, USA – September 17, 2026 – Creative Bioarray, a premier provider of advanced research solutions in biomedicine, is a global biotechnology research company providing discovery, preclinical, and translational platforms and services to advance oncology and immuno-oncology. Recently, Creative Bioarray is thrilled to announce the debut of its cutting-edge organoid platform which is set to revolutionize the fields of drug development and biomedical research by providing researchers with tools that significantly improve predictive accuracy and facilitate personalized medicine initiatives.
Organoids, which are sophisticated three-dimensional (3D) cellular structures, replicate the architecture and function of human organs. By harnessing the power of these organoids alongside organoid-immune co-culture models, Creative Bioarray empowers researchers to simulate in vivo conditions more effectively than traditional two-dimensional (2D) cell cultures. Creative Bioarray offers cutting-edge services leveraging patient-derived organoid technology to support drug discovery, disease modeling, and personalized medicine. Creative Bioarray’s service portfolio includes drug screening, custom assay development, and co-clinical testing through clinical trials in a dish.
“The introduction of our organoid platform marks an important milestone in our commitment to enhancing drug discovery and development processes,” stated Hannah Cole, Marketing Director at Creative Bioarray. “Our innovative platform not only streamlines drug screening and toxicity assessments but also opens new avenues for personalized medicine, enabling tailored therapeutic strategies and better outcomes for patients.”
Creative Bioarray offers access to a wide array of organoids that represent over twenty different tissue types, including organs such as the brain, liver, pancreas, and intestine. This diversity allows for extensive research applications across various medical fields. Creative Bioarray closely recapitulate patient pathobiology, providing superior preclinical models for your compound testing and closing the gap to clinical trials. Creative Bioarray can support decision-making at every step of your drug development pipeline and help you bring life-changing treatments to patients.
Leveraging patient-derived organoid technology, we provide tailored solutions across therapeutic areas such as oncology, inflammatory diseases, genetic disorders, and toxicology. With the innovative approach, Creative Bioarray helps reduce drug attrition rates and unravel the complexity of human diseases. The organoid platform supports multiple research applications that are critical for advancing modern medicine.
“By using tumor-derived organoids, researchers can model different cancer types to study tumor behavior, investigate treatment responses, and develop new cancer therapeutics.” said Hannah Cole, she also added, “besides, we also focus on the research for drug toxicity, infectious disease modeling and regenerative medicine.”
With the launch of its organoid platform, Creative Bioarray is solidifying its role as a frontrunner in the field of biomedicine and drug development. The company remains committed to fostering innovation that aligns with the evolving needs of researchers and healthcare professionals striving for improved patient outcomes.
About Creative Bioarray
Creative Bioarray specializes in translational oncology and immuno-oncology drug discovery and development. Our preclinical and translational services enable biotech and pharmaceutical companies to empower customers to improve human health across the globe. Creative Bioarray engages the finest scientific talent, uphold the highest quality standards, and relentlessly pursue innovation.
Media ContactCompany Name: Creative BioarrayContact Person: Hannah ColeEmail: Send EmailPhone: 16313868241Address:Shirley, NY 11967, USA City: ShirleyState: New YorkCountry: United StatesWebsite: https://www.creative-bioarray.com/
